United States Biotechnology & Medical Research

Xeris Pharmaceuticals Inc (XERS)

Track

Ticker: XERS Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
PRESTRELSKI STEVEN
Chief Scientific Officer
1 sale — total 60,058 USD
Planned sale 13 Jan 2021
Value US$2,818,856.19 | Price 91.42 | Shares 47,053
Planned sale 11 Jan 2021
Value US$1,984,102.54 | Price 61.20 | Shares 85,695
Buy 9 Dec 2020
Value US$40,551.00 | Price 4.06 | Shares 10,000
Buy 13 May 2020
Value US$77,994.40 | Price 3.55 | Shares 22,000
Buy 8 May 2020
Value US$25,219.43 | Price 3.20 | Shares 7,886
Buy 8 May 2020
Value US$99,000.00 | Price 3.00 | Shares 33,000
Buy 13 Mar 2020
Value US$7,880.00 | Price 1.97 | Shares 4,000
Buy 14 Feb 2020
Value US$16,600.00 | Price 4.15 | Shares 4,000
Buy 14 Feb 2020
Value US$83,000.00 | Price 4.15 | Shares 20,000
Buy 14 Feb 2020
Value US$40,001.85 | Price 4.15 | Shares 9,639
Buy 14 Feb 2020
Value US$49,999.20 | Price 4.15 | Shares 12,048
Buy 14 Feb 2020
Value US$10,001.50 | Price 4.15 | Shares 2,410
Planned sale 13 Jan 2020
Value US$54,992.00 | Price 5.50 | Shares 10,000
Buy 25 Nov 2019
Value US$153,283.27 | Price 8.55 | Shares 17,935
Planned sale 11 Oct 2019
Value US$79,746.00 | Price 7.97 | Shares 10,000
Planned sale 11 Jul 2019
Value US$482.60 | Price 12.70 | Shares 38
Planned sale 11 Jul 2019
Value US$119,912.59 | Price 12.04 | Shares 9,962
Planned sale 11 Apr 2019
Value US$95,649.00 | Price 9.56 | Shares 10,000
Buy 11 Mar 2019
Value US$273,585.00 | Price 9.12 | Shares 30,000
Buy 19 Feb 2019
Value US$10,000.00 | Price 10.00 | Shares 1,000
Buy 19 Feb 2019
Value US$50,000.00 | Price 10.00 | Shares 5,000
Buy 19 Feb 2019
Value US$25,000.00 | Price 10.00 | Shares 2,500
Buy 19 Feb 2019
Value US$5,880,000.00 | Price 10.00 | Shares 588,000
Sale 11 Feb 2019
Value US$20,265.00 | Price 15.00 | Shares 1,351
Sale 8 Feb 2019
Value US$88,985.53 | Price 15.11 | Shares 5,890
Sale 7 Feb 2019
Value US$141,135.00 | Price 15.00 | Shares 9,409
Sale 6 Feb 2019
Value US$6,000.00 | Price 15.00 | Shares 400
Sale 5 Feb 2019
Value US$75,307.86 | Price 15.07 | Shares 4,998
Sale 29 Jan 2019
Value US$94,028.09 | Price 15.14 | Shares 6,210
Sale 28 Jan 2019
Value US$12,420.00 | Price 15.00 | Shares 828
Sale 25 Jan 2019
Value US$1,158,253.55 | Price 15.08 | Shares 76,820
Sale 24 Jan 2019
Value US$81,562.70 | Price 15.03 | Shares 5,425
Sale 23 Jan 2019
Value US$526,376.37 | Price 16.35 | Shares 32,199
Planned sale 14 Jan 2019
Value US$132,459.25 | Price 17.20 | Shares 7,700
Planned sale 11 Jan 2019
Value US$0.00 | Price 0.00 | Shares 2,300
Sale 26 Dec 2018
Value US$248,737.56 | Price 15.82 | Shares 15,720
Buy 25 Jun 2018
Value US$10,000,020.00 | Price 15.00 | Shares 666,668
Buy 25 Jun 2018
Value US$9,364,995.00 | Price 15.00 | Shares 624,333
Buy 25 Jun 2018
Value US$1,885,005.00 | Price 15.00 | Shares 125,667
Buy 25 Jun 2018
Value US$2,250,000.00 | Price 15.00 | Shares 150,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2021-01-15 2021-01-13 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer

Officer
47,053 -16.9%
91.42
US$2,818,856 		47,053 -16.9% 91.42 US$2,818,856
2021-01-12 2021-01-11 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer

Officer
85,695 -2.1%
61.20
US$1,984,103 		85,695 -2.1% 61.20 US$1,984,103
2020-12-10 2020-12-09 B Purchase
3.8
Edick Paul R

See Remarks

Executive Director
38,859 -49.7%
244.53
US$1,575,577 		38,859 -49.7% 244.53 US$1,575,577
2020-05-14 2020-05-13 B Purchase
3.8
Shannon John Patrick Jr

See Remarks

Officer
22,000 +23.0%
3.55
US$77,994 		22,000 +23.0% 3.55 US$77,994
2020-05-11 2020-05-08 B Purchase
3.8
Shannon John Patrick Jr

See Remarks

Officer
7,886 +9.0%
3.20
US$25,219 		7,886 +9.0% 3.20 US$25,219
2020-05-11 2020-05-08 B Purchase
3.8
Edick Paul R

See Remarks

Executive Director
33,000 +9.0%
3.00
US$99,000 		33,000 +9.0% 3.00 US$99,000
2020-03-16 2020-03-13 B Purchase
3.1
Hecht Beth

See Remarks

Officer
4,000 +7.5%
1.97
US$7,880 		4,000 +7.5% 1.97 US$7,880
2020-02-18 2020-02-14 B Purchase
3.1
Hecht Beth

See Remarks

Officer
4,000 +98.0%
4.15
US$16,600 		4,000 +98.0% 4.15 US$16,600
2020-02-18 2020-02-14 B Purchase
3.8
Edick Paul R

See Remarks

Executive Director
20,000 +12.3%
4.15
US$83,000 		20,000 +12.3% 4.15 US$83,000
2020-02-18 2020-02-14 B Purchase
Deutsch Barry M.

See Remarks

Officer
9,639 +32.4%
4.15
US$40,002 		9,639 +32.4% 4.15 US$40,002
2020-02-18 2020-02-14 B Purchase
3.8
Shannon John Patrick Jr

See Remarks

Officer
12,048 +114.1%
4.15
US$49,999 		12,048 +114.1% 4.15 US$49,999
2020-02-18 2020-02-14 B Purchase
JOHNSON KENNETH ERLAND

See Remarks

Officer
2,410 +65.0%
4.15
US$10,002 		2,410 +65.0% 4.15 US$10,002
2020-01-14 2020-01-13 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer
10,000 -2.3%
5.50
US$54,992 		10,000 -2.3% 5.50 US$54,992
2019-11-27 2019-11-25 B Purchase
3.8
Edick Paul R

See Remarks

Executive Director
17,935 +11.6%
8.55
US$153,283 		17,935 +11.6% 8.55 US$153,283
2019-10-16 2019-10-11 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer
10,000 -2.2%
7.97
US$79,746 		10,000 -2.2% 7.97 US$79,746
2019-10-16 2019-07-11 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer
38 -0.0%
12.70
US$483 		38 -0.0% 12.70 US$483
2019-10-16 2019-07-11 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer
9,962 -2.1%
12.04
US$119,913 		9,962 -2.1% 12.04 US$119,913
2019-04-12 2019-04-11 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer
10,000 -2.1%
9.56
US$95,649 		10,000 -2.1% 9.56 US$95,649
2019-03-12 2019-03-11 B Purchase
3.8
Edick Paul R

See Remarks

Executive Director
30,000 +24.0%
9.12
US$273,585 		30,000 +24.0% 9.12 US$273,585
2019-02-25 2019-02-19 B Purchase
JOHNSON KENNETH ERLAND

See Remarks

Officer
1,000 +44.5%
10.00
US$10,000 		1,000 +44.5% 10.00 US$10,000
2019-02-22 2019-02-19 B Purchase
Deutsch Barry M.

See Remarks

Officer
5,000 +21.5%
10.00
US$50,000 		5,000 +21.5% 10.00 US$50,000
2019-02-22 2019-02-19 B Purchase
3.1
Hecht Beth

See Remarks

Officer
2,500 +inf%
10.00
US$25,000 		2,500 +inf% 10.00 US$25,000
2019-02-21 2019-02-19 B Purchase
3.2
Redmile Group, LLC
Large shareholder
588,000 +24.4%
10.00
US$5,880,000 		588,000 +24.4% 10.00 US$5,880,000
2019-02-12 2019-02-11 S Sale
2.8
Flynn James E
Large shareholder
1,351 -0.2%
15.00
US$20,265 		1,351 -0.2% 15.00 US$20,265
2019-02-12 2019-02-08 S Sale
2.8
Flynn James E
Large shareholder
5,890 -0.7%
15.11
US$88,986 		5,890 -0.7% 15.11 US$88,986
2019-02-07 2019-02-07 S Sale
2.8
Flynn James E
Large shareholder
9,409 -1.1%
15.00
US$141,135 		9,409 -1.1% 15.00 US$141,135
2019-02-07 2019-02-06 S Sale
2.8
Flynn James E
Large shareholder
400 -0.0%
15.00
US$6,000 		400 -0.0% 15.00 US$6,000
2019-02-07 2019-02-05 S Sale
2.8
Flynn James E
Large shareholder
4,998 -0.6%
15.07
US$75,308 		4,998 -0.6% 15.07 US$75,308
2019-01-30 2019-01-29 S Sale
2.8
Flynn James E
Large shareholder
6,210 -0.7%
15.14
US$94,028 		6,210 -0.7% 15.14 US$94,028
2019-01-30 2019-01-28 S Sale
2.8
Flynn James E
Large shareholder
828 -0.1%
15.00
US$12,420 		828 -0.1% 15.00 US$12,420
2019-01-25 2019-01-25 S Sale
2.8
Flynn James E
Large shareholder
76,820 -8.0%
15.08
US$1,158,254 		76,820 -8.0% 15.08 US$1,158,254
2019-01-25 2019-01-24 S Sale
2.8
Flynn James E
Large shareholder
5,425 -0.6%
15.03
US$81,563 		5,425 -0.6% 15.03 US$81,563
2019-01-25 2019-01-23 S Sale
2.8
Flynn James E
Large shareholder
32,199 -3.2%
16.35
US$526,376 		32,199 -3.2% 16.35 US$526,376
2019-10-16 2019-01-14 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer
7,700 -1.6%
17.20
US$132,459 		7,700 -1.6% 17.20 US$132,459
2019-01-15 2019-01-11 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer

Officer
2,300
0.00
US$0 		2,300 0.00 US$0
2019-01-02 2018-12-26 S Sale
PRESTRELSKI STEVEN

Chief Scientific Officer

Officer
15,720 -3.1%
15.82
US$248,738 		15,720 -3.1% 15.82 US$248,738
2018-06-27 2018-06-25 B Purchase Redmile Group, LLC
666,668 +38.2%
15.00
US$10,000,020 		666,668 +38.2% 15.00 US$10,000,020
2018-06-27 2018-06-25 B Purchase Flynn James E Large shareholder
624,333 +71.4%
15.00
US$9,364,995 		624,333 +71.4% 15.00 US$9,364,995
2018-06-27 2018-06-25 B Purchase Flynn James E Large shareholder
125,667 +14.4%
15.00
US$1,885,005 		125,667 +14.4% 15.00 US$1,885,005
2018-06-25 2018-06-25 B Purchase Palmetto Partners, Ltd. Large shareholder
150,000 +7.7%
15.00
US$2,250,000 		150,000 +7.7% 15.00 US$2,250,000
Explore more

More insider trading research around Xeris Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America